2 min read

Abbott India Moat Analysis: Score & Risks

Moat Note · First-pass

Abbott India Ltd.

A first-pass moat teardown of Abbott India Ltd., built from single-pass filing evidence. Free note — provisional, and the full two-pass deep dive may revise it.

Moat & Margin16 Aug 2026 First-pass · ~3 min
5.29 / 10
NARROWProcess/Data-led

First-pass narrow read — primary edge in Network Effects. Provisional, single-pass evidence.

Provisional score · subject to modification based on new evidence

Abbott India Ltd. scores 5.29 on MoatSCORE 6.0 — a narrow moat in Pharma. This is a first-pass note: the dimensional read and the filing receipts below come from a single GFIP evidence pass, not the full two-pass deep corpus behind our flagship deep dives. Provisional — published free while the deep version is queued.

The teardown

Seven dimensions of moat

Ordered by contribution. Each dimension carries a verified filing quote, graded [M] mechanism or [O] outcome.

D1Network Effects6
M · Mechanism Verified verbatim

“We have a robust distribution network of more than 8,600 stockists and 60 Lakhs retailers.”

Abbott India Ltd. · FY2022-07 Annual Report · p.6
D4Price Discretion6
M · Mechanism Verified verbatim

“Severe price pressure is expected due to expansion of pricing regulations and increasing regulatory interventions.”

Abbott India Ltd. · FY2020 Annual Report · p.32
D5Intangible Assets5.7
M · Mechanism Verified verbatim

“16* of our brands are market leaders (ranked #1 or #2) in their respective participated markets.”

Abbott India Ltd. · FY2025 Annual Report · p.9
D2Switching Costs5.5
M · Mechanism Verified verbatim

“We move from therapy shaping to diagnosis, to the pill, or the medicine. But we go beyond the pill, we focus on adherence, we focus on patient care.”

Abbott India Ltd. · Earnings Call · p.4
D3Cost Advantage5.5
M · Mechanism Verified verbatim

“Optimum utilization of manufacturing operations, upgradation of processes, and responsible partnerships with local manufacturers, enhance efficiency and productivity, while reducing cost and ensuring best quality standards.”

Abbott India Ltd. · FY2022-07 Annual Report · p.19
D6Efficient Scale5.5
No verified filing quote surfaced for this dimension in the first-pass evidence sweep.
D7Counter-PositioningExcluded
Excluded for this archetype.
D8Ungoverned RiskUnscored · Layer 2.5

D8 rating: ADEQUATE. Not part of the moat score — it governs the cost of equity and the fade window. First-pass; not yet deep-reviewed.

The barrier gate

The barrier gate — first-pass

Replication — can a rival copy it?6.0
How hard it is for a rival to copy the edge (first-pass estimate).
Bypass — can a rival route around it?6.0
How easily a rival can route around the edge (first-pass estimate).

Effective barrier 6 — at or above 6, consistent with a narrow read. First-pass estimate.

What would change our mind
  1. Deep two-pass review. This draft rests on a single GFIP evidence pass; the full 10-year AR + concall corpus may move the read.

  2. The barrier gate. A firmer replication or bypass estimate is the most likely thing to shift the band.

  3. Adverse events. Any governance, regulatory or funding shock captured in D8 could re-rate the fade window.

First-pass note — provisional single-pass MoatSCORE 6.0 read, not the full deep dive. Educational research, not investment advice; no buy/sell recommendation, no price target. Moat & Margin is not a SEBI-registered Research Analyst or Investment Adviser.